Published in Evid Based Complement Alternat Med on March 21, 2016
Therapeutic Strategies for Oxidative Stress-Related Cardiovascular Diseases: Removal of Excess Reactive Oxygen Species in Adult Stem Cells. Oxid Med Cell Longev (2016) 0.80
Rapidly directional biotransformation of tauroursodeoxycholic acid through engineered Escherichia coli. J Ind Microbiol Biotechnol (2017) 0.75
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol (2010) 2.02
Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology (2002) 1.98
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol (2008) 1.72
Use of animal products in traditional Chinese medicine: environmental impact and health hazards. Complement Ther Med (2003) 1.60
Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipients. Transplantation (2001) 1.53
Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem (2010) 1.42
Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed (2009) 1.12
Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol (2012) 1.09
Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut (2008) 1.09
Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. J Ethnopharmacol (2011) 1.04
Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer (2010) 0.99
Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta (2014) 0.98
Ursodeoxycholic acid in chronic liver disease. Gut (1991) 0.97
Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res (2007) 0.97
Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology (1993) 0.97
Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev (2002) 0.96
Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat. Am J Chin Med (2007) 0.95
Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor (2009) 0.94
A stated preference investigation into the Chinese demand for farmed vs. wild bear bile. PLoS One (2011) 0.93
Differentiation of various traditional Chinese medicines derived from animal bile and gallstone: simultaneous determination of bile acids by liquid chromatography coupled with triple quadrupole mass spectrometry. J Chromatogr A (2010) 0.93
Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion (2011) 0.91
Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology (2001) 0.91
Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem Biophys Res Commun (2007) 0.91
Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol (2006) 0.90
Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. Lab Invest (2014) 0.88
Ursodeoxycholic acid treatment for chronic cholestatic liver disease. J Hepatol (1990) 0.87
Ethnopharmacology of bear gall bladder: I. J Ethnopharmacol (1995) 0.87
[Comparison between pharmacologic actions of rabbit bile and bear bile]. Zhongguo Zhong Yao Za Zhi (1994) 0.86
Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review. World J Gastroenterol (2014) 0.85
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol (2007) 0.85
Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. Chin Med (2012) 0.85
Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells. Ann N Y Acad Sci (2009) 0.84
Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo. Int J Oncol (2005) 0.83
A comparative study on the hepatoprotective action of bear bile and Coptidis Rhizoma aqueous extract on experimental liver fibrosis in rats. BMC Complement Altern Med (2012) 0.83
Ursodeoxycholic acid for nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2012) 0.81
Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet. Dig Dis Sci (2014) 0.80
Liver regeneration enhanced by orally administered ursodesoxycholic acid is mediated by immunosuppression in partially hepatectomized rats. Am J Chin Med (2002) 0.80
Roles of bile acid conjugates and phospholipids in in vitro activation of pancreatic lipase by bear bile and cattle bile. J Ethnopharmacol (2009) 0.80
Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma. Integr Cancer Ther (2013) 0.80
Novel bile acids from bear bile powder and bile of geese. Chem Pharm Bull (Tokyo) (2009) 0.79
Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol (2005) 0.79
Chemical and biological analysis of active free and conjugated bile acids in animal bile using HPLC-ELSD and MTT methods. Exp Ther Med (2010) 0.78
Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure. Oncotarget (2015) 0.78
Bear bile inhibits the immunosuppression activity of hepatic stellate cells in vivo. Hepatogastroenterology (2012) 0.77
[Influence of bear bile on rat hepatocarcinoma induced by diethylnitrosamine]. Yao Xue Xue Bao (2012) 0.77
Cattle bile but not bear bile or pig bile induces lipid profile changes and fatty liver injury in mice: mediation by cholic acid. J Toxicol Sci (2012) 0.77
[Structure determination of three novel bile acids from bear bile powder]. Yao Xue Xue Bao (2013) 0.77
[Advances in studies on bear bile powder]. Zhongguo Zhong Yao Za Zhi (2015) 0.76
Bear bile powder inhibits angiogenesis in vivo and in vitro. Chin J Integr Med (2015) 0.76
[Chemical constituents of bear bile]. Zhongguo Zhong Yao Za Zhi (2010) 0.76
Metabolomics and proteomics approaches to characterize and assess proteins of bear bile powder for hepatitis C virus. Chin J Nat Med (2013) 0.76
Bear bile powder (熊胆粉) induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway. Chin J Integr Med (2014) 0.76
[Study on inhibitory effect of combined administration of bear bile powder and cyclophosphamide on colorectal cancer liver metastasis by regulating tumor microenvironment]. Zhongguo Zhong Yao Za Zhi (2013) 0.76
[Analysis on replacement of traditional Chinese medicine bear bile with bile acids based on drug properties]. Zhongguo Zhong Yao Za Zhi (2014) 0.76
[Effect of bear bile powder on STAT3 pathway in hepatocellular carcinoma xenograft]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2014) 0.76
The Reactive Oxygen Species in Macrophage Polarization: Reflecting Its Dual Role in Progression and Treatment of Human Diseases. Oxid Med Cell Longev (2016) 0.80
Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases. Oxid Med Cell Longev (2016) 0.80
Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective. Evid Based Complement Alternat Med (2016) 0.79
Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells. Evid Based Complement Alternat Med (2016) 0.79
Network Pharmacology-Based Approach to Investigate the Analgesic Efficacy and Molecular Targets of Xuangui Dropping Pill for Treating Primary Dysmenorrhea. Evid Based Complement Alternat Med (2017) 0.75